

MISSION

Pancreatic ductal adenocarcinoma is a deadly form of cancer that is on the rise due to various factors, including an aging population and unhealthy lifestyles.


It is regrettably among the top cancer killers, with a dismal five-year survival rate of less than 10%.

No adequate screening programs are available at the time being. Our mission is to create a test for mass screening and reduce the mortality of this cancer by 80%.

OBJECTIVE

The project LASERBLOOD aims to develop an in vitro diagnostic test based on the fluorescence lifetime fingerprint of nanoparticle coated disease-specific markers, offering critical information of pancreatic cancer progression.

The project will create of a non-invasive liquid biopsy for pancreatic cancer, a blood test that will detect signs of cancer at every stage. The technology will be based on fluorescence lifetime analysis, a reactant-free, real-time, laser-based technique.



LASERBLOOD

E I C P A T H F I N D E R

Coordinator

**FLIM
LABS**[®]

Partners



SAPIENZA
UNIVERSITÀ DI ROMA



FONDAZIONE
POLICLINICO UNIVERSITARIO
CAMPUS BIO-MEDICO

IRE
ISTITUTO NAZIONALE TUMORI
REGINA ELENA

ISG
ISTITUTO DERMATOLOGICO
SAN GALLICANO
ISTITUTI DI RICOVERO E CURA A CARATTERE SCIENTIFICO


IRCCS
ISTITUTI FISIOTERAPICI
OSPITALIERI

SISTEMA SANITARIO REGIONALE

**Uniklinikum
Erlangen**



CrowdHelix



LASERBLOOD

E I C P A T H F I N D E R

European
Innovation
Council



Funded by
the European Union


www.laserblood.eu

IMPLEMENTATION


PHASE A



Blood samples are collected from a genetically engineered mouse model that develops pancreatic cancer in a controlled manner.




Fluorescence lifetime analysis on nano-particle enriched blood samples is used to monitor the progression of pancreatic cancer from its first occurrence.





PHASE B



The results from phase A are validated on humans via blood sample collection from patients with ongoing pancreatic cancer and patients with a high probability of developing the disease.



The LASERBLOOD liquid biopsy technology is created for mass screening of the population.



PARTNERS

FLIM LABS, Italy



UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA, Italy



SAPIENZA
UNIVERSITÀ DI ROMA

FONDAZIONE POLICLINICO UNIVERSITARIO CAMPUS BIO MEDICO, Italy



FONDAZIONE
POLICLINICO UNIVERSITARIO
CAMPUS BIO-MEDICO

UNIVERSITÄTSKLINIKUM ERLANGEN, Germany

Uniklinikum Erlangen

ISTITUTI FISIOTERAPICI OSPITALIERI, Italy



ISTITUTO NAZIONALE SANI REGINA ELENA
SCUOLA SUPERIORE DI SAN GALLICIANO
ISTITUTO RICERCHI E CURA A CARATTERI SCIENTIFICI

SISTEMA SANITARIO REGIONALE
IRCCS
ISTITUTI FISIOTERAPICI
OSPITALIERI

CROWDHELIX LIMITED, Ireland

